Pipeline

Company Program Drug Mechansim Indication Discovery Preclinical IND Phase 1 Phase 2
NLY01 - PD
GLP1R agonist
Parkinson’s disease
NLY01 - D
GLP1R agonist
Type 2 diabetes
P4M01
Antibacterial
Periodontal disease
NLY01 - AD
GLP1R agonist
Alzheimer's disease
PMI01
TSPO targeting PET/SPECT tracer
Neuroinflammation
PMI03
sEH targeting PET tracer
Neuroinflammation
PMI04
CSF1R targeting PET/SPECT tracer
Neuroinflammation
PMI05
CAIX targeting PET/SPECT tracer
Oncology
PMI06
PD-L1 targeting PET tracer
Oncology
TLY012
DR5 agonist
NASH-liver fibrosis
TLY012
DR5 agonist
Chronic pancreatitis
TLY012
DR5 agonist
Systemic sclerosis
TLY014
Undisclosed
Pancreatic cancer
DD01
GLP1R/GCCR agonist
Severe obesity, NASH
NLY02
Undisclosed
Parkinson’s disease/ Alzheimer’s disease
NLY03
Undisclosed
Stroke, Parkinson’s disease
DD02
Oral, GLP1R agonist
Type 2 diabetes
DD03
Oral, GLP1R/GCGR/GIPR agonist
Obesity, NASH